NCT03940053 is a Phase 3 clinical trial of Arginine hydrochloride in Cancer, sponsored by Zujiang YU.

Who is sponsoring NCT03940053?

NCT03940053 is sponsored by Zujiang YU.

What drugs are being tested in NCT03940053?

Interventions in NCT03940053: Arginine hydrochloride.

Is NCT03940053 still recruiting?

NCT03940053 is currently status unknown. Last updated 7 May 2019.

Last reviewed 2019-05-07 · How we verify

NCT03940053

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Cancer Development and Progression

Status unknown Phase 3 Last updated 7 May 2019

What this trial tests

Phase 3 trial testing Arginine hydrochloride in Cancer in 300 participants. Status unknown.

Timeline

10 May 2019

Primary endpoint
10 August 2024

10 May 2025

Quick facts

Lead sponsor	Zujiang YU
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	300
Start date	10 May 2019
Primary completion	10 August 2024
Estimated completion	10 May 2025

Drugs / interventions tested

Arginine hydrochloride — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Zujiang YU

Who can join

Adults 40 to 70, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of arginine in preventing cancer development

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Arginine hydrochloride

Trials testing the same drug.

NCT07167693 — Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes · Phase 1, PHASE2 · recruiting
NCT03950518 — Novel Treatment of Advanced Hepatocellular Carcinoma · Phase 3 · unknown

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03940053 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zujiang YU
Last refreshed: 7 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03940053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing